Comera Life Sciences Holdings, Inc. CMRA
We take great care to ensure that the data presented and summarized in this overview for Comera Life Sciences Holdings, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CMRA
View allLatest Institutional Activity in CMRA
Top Purchases
Top Sells
About CMRA
Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.
Insider Transactions at CMRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 27
2023
|
Michael Gerard Campbell EVP & CFO |
BUY
Open market or private purchase
|
Direct |
10,000
+22.22%
|
$0
$0.07 P/Share
|
|
Nov 15
2023
|
William A. Wexler Director |
BUY
Other acquisition or disposition
|
Direct |
3,113
+13.01%
|
-
|
|
Sep 11
2023
|
David Soane > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
117,360
+17.11%
|
$0
$0.51 P/Share
|
|
Sep 11
2023
|
Charles Cherington > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
2,053,789
+26.1%
|
$0
$0.51 P/Share
|
|
Aug 14
2023
|
Robert Patrick Mahoney Chief Scientific Officer |
BUY
Open market or private purchase
|
Direct |
20,000
+13.83%
|
$0
$0.63 P/Share
|
|
Aug 11
2023
|
William A. Wexler Director |
BUY
Other acquisition or disposition
|
Direct |
6,636
+27.27%
|
-
|
|
Jul 31
2023
|
Charles Cherington > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
880,195
+18.97%
|
$0
$0.51 P/Share
|
|
Jul 31
2023
|
David Soane > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
273,838
+37.76%
|
$0
$0.51 P/Share
|
|
Jan 04
2023
|
Charles Cherington > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
743,243
+20.52%
|
$743,243
$1.23 P/Share
|
|
Jan 04
2023
|
Kirsten Flowers Director |
BUY
Grant, award, or other acquisition
|
Direct |
13,513
+37.84%
|
$13,513
$1.23 P/Share
|
|
Jan 04
2023
|
Edward Aloysius Sullivan Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
10,979
+35.83%
|
$10,979
$1.23 P/Share
|
|
Jan 04
2023
|
Stuart A Randle Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,783
+44.3%
|
$33,783
$1.23 P/Share
|
|
Jan 04
2023
|
James Sherblom Director |
BUY
Grant, award, or other acquisition
|
Direct |
81,081
+15.2%
|
$81,081
$1.23 P/Share
|
|
Jan 04
2023
|
Barbara K Finck Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,756
+22.68%
|
$6,756
$1.23 P/Share
|
|
Jan 04
2023
|
Sirshendu Roopom Banerjee Director |
BUY
Grant, award, or other acquisition
|
Direct |
20,270
+41.18%
|
$20,270
$1.23 P/Share
|
|
Jan 04
2023
|
David Soane > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
202,701
+29.48%
|
$202,701
$1.23 P/Share
|
|
Nov 08
2022
|
David Soane > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,000
+0.09%
|
$3,000
$1.38 P/Share
|
|
Oct 21
2022
|
Charles Cherington > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
11,691
+1.77%
|
$11,691
$1.59 P/Share
|
|
Oct 20
2022
|
Charles Cherington > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
3,316
+0.52%
|
$3,316
$1.52 P/Share
|
|
Oct 17
2022
|
Charles Cherington > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
15,266
+2.35%
|
$15,266
$1.66 P/Share
|